AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Sarcoidosis

Recent research efforts aimed at curing Sarcoidosis.

Last updated
Also available in
Français — Sarcoïdose

Sarcoidosis

Overview

Sarcoidosis is an inflammatory disease in which the immune system forms clusters of immune cells called noncaseating granulomas in affected tissue. It can involve almost any organ, but the lungs and chest lymph nodes are most often affected; symptoms range from none to cough, breathlessness, fatigue, skin lesions, eye disease, and, less commonly, potentially dangerous heart or nervous-system involvement. It can affect people at any age, and its course is highly variable. About half of patients experience remission within two years, while a substantial minority develop persistent, progressive, or organ-threatening disease. Sarcoidosis: Evaluation and Treatment ERS clinical practice guidelines

There is currently no proven therapy that cures sarcoidosis by eliminating its underlying cause or reliably preventing relapse permanently. Many people with mild disease can be monitored without treatment. For symptomatic, progressive, or organ-threatening disease, corticosteroids such as prednisone remain standard first-line treatment; methotrexate and other immune-suppressing medicines are used to reduce steroid exposure, while biologic anti-TNF drugs may be considered in selected refractory cases. Long-term treatment decisions must balance inflammation control against medication toxicity and irreversible organ damage. ERS clinical practice guidelines First-Line Treatment with Prednisone or Methotrexate

Scope of Recent Research (2020–present)

Research activity has increased meaningfully since 2020, particularly around more targeted immune therapies, steroid-sparing treatment, molecular subtypes of disease, and biomarkers that can distinguish active inflammation from permanent scarring. The central question is no longer simply whether broad immunosuppression works, but which immune pathways drive granulomas in particular patients and whether treatment can produce durable, drug-free remission. Despite this progress, the field is still pursuing disease control and prevention of damage rather than a demonstrated cure; recent late-stage trial disappointments illustrate how far there is to go. Sarcoidosis: A Clinical Trials Perspective New Therapies for Sarcoidosis

Major Breakthroughs and Emerging Therapies

The strongest practical advance has been a shift toward reducing reliance on corticosteroids. In the 2025 PREDMETH noninferiority trial, 138 previously untreated patients with pulmonary sarcoidosis were assigned to prednisone or methotrexate. Methotrexate was noninferior to prednisone for improvement in forced vital capacity at 24 weeks, although the two treatments had different side-effect profiles. This does not cure sarcoidosis, but it provides higher-quality evidence that some patients can begin with a steroid-sparing strategy rather than assuming prednisone is mandatory. First-Line Treatment with Prednisone or Methotrexate The earlier SARCORT randomized trial likewise found no advantage for an initial 40-mg prednisolone dose over 20 mg, reinforcing efforts to limit unnecessary steroid exposure. SARCORT trial

JAK inhibition is one of the most biologically compelling targeted approaches. Janus kinase–signal transducer and activator of transcription (JAK-STAT) signaling helps transmit inflammatory signals used by T cells and macrophages, two cell types central to granuloma formation. A small prospective open-label study found that tofacitinib enabled 3 of 5 patients with pulmonary sarcoidosis to taper corticosteroids successfully; a 2020 multiorgan case report also described remission of skin disease and resolution of PET-active internal lesions after six months. These findings are promising but are not proof of cure because they come from small, uncontrolled studies and require confirmation in larger randomized trials. Tofacitinib proof-of-concept study Multiorgan sarcoidosis treated with tofacitinib

A related strategy is selective JAK1 inhibition with abrocitinib. Yale University completed a 10-person Phase 2, open-label study in moderate-to-severe cutaneous sarcoidosis in April 2025. The trial incorporated skin-disease scoring, whole-body PET-CT imaging, quality-of-life measures, blood biomarkers, and tissue-and-blood immune profiling, but results had not been posted in the registry record. This is an example of the field pairing a targeted treatment with molecular measurements to identify who responds and why. JAK1 Inhibition in Sarcoidosis

Macrophage- and granuloma-directed biologics have produced mixed but informative results. Efzofitimod, an intravenous immunomodulator developed by aTyr Pharma that targets neuropilin-2, showed steroid-reducing and symptom-related signals in a Phase 1b/2a study. However, in the 268-person Phase 3 EFZO-FIT trial, it did not meet the primary endpoint of reducing average daily oral corticosteroid dose at week 48. Company-reported secondary analyses suggested improved lung-related quality of life and a higher proportion of patients achieving both steroid withdrawal and improved lung questionnaire scores, but these findings are nominal because the primary endpoint was missed. Efzofitimod Phase 1b/2a study EFZO-FIT registry record EFZO-FIT topline results

Other cytokine-blocking strategies have also tested whether turning off a single inflammatory signal can dismantle chronic granulomas. In the 2026 Phase 2 RESOLVE-Lung trial, the anti-GM-CSF antibody namilumab did not provide clinical benefit in chronic active pulmonary sarcoidosis. This negative result does not invalidate macrophage biology as a target, but it suggests that blocking one cytokine alone may be insufficient in a disease with multiple overlapping immune pathways. RESOLVE-Lung namilumab trial New Therapies for Sarcoidosis

There are no established gene therapies, gene-editing treatments, RNA medicines, or cell therapies for sarcoidosis as of August 8, 2026. Instead, curative research remains focused on identifying and interrupting the immune circuits that maintain granulomas, including JAK-STAT, TNF, mTOR metabolic signaling, and macrophage–T-cell communication. New Therapies for Sarcoidosis Single-cell and spatial transcriptomics study

Clinical Trials and Experimental Approaches

The largest recent interventional study was aTyr Pharma’s global Phase 3 EFZO-FIT trial of intravenous efzofitimod in pulmonary sarcoidosis. The randomized, double-blind, placebo-controlled study enrolled 268 adults receiving stable corticosteroid treatment, with or without another immunosuppressant. It completed in July 2025; although it missed its primary steroid-reduction endpoint, the trial remains important because it demonstrated that large multinational sarcoidosis trials using standardized steroid tapers and patient-reported outcomes are feasible. EFZO-FIT registry record EFZO-FIT topline results

Several earlier-stage studies test pathway-specific medicines rather than broadly suppressing immunity. Yale’s Phase 2 abrocitinib study tested JAK1 inhibition in 10 people with cutaneous sarcoidosis. A separate Xentria-sponsored Phase 1b/2 study began in 2023 to test XTMAB-16, an anti-TNF-α monoclonal antibody, in pulmonary sarcoidosis with or without extrapulmonary disease; its registry design included randomized, placebo-controlled dose-finding followed by a proof-of-concept stage. A 16-week clinical study has also evaluated the mTOR inhibitor sirolimus in cutaneous sarcoidosis, based on evidence that metabolic reprogramming may help sustain granulomas. JAK1 Inhibition in Sarcoidosis XTMAB-16 trial Sirolimus in Cutaneous Sarcoidosis

Testing the theory that persistent microbial antigens cause some sarcoidosis cases has not yet yielded a curative approach. In a randomized Phase 2 trial of broad antimycobacterial treatment—CLEAR: levofloxacin, ethambutol, azithromycin, and rifampin—patients with chronic pulmonary sarcoidosis had no significant improvement in lung function compared with placebo. The result weakens the case for using this regimen broadly, while leaving open the possibility that a biologically defined subgroup could have a different trigger. CLEAR pulmonary sarcoidosis trial

Methodologies and Scientific Approaches

Researchers increasingly study sarcoidosis at the level of individual cells and their locations within granulomas. Single-cell RNA sequencing measures which genes are active in thousands of individual cells, while spatial transcriptomics maps those cells and gene programs within diseased tissue. A recent study of sarcoidosis granulomas identified metabolically altered macrophages, inflammatory Th17.1 T cells, and tissue-remodeling fibroblasts as central components of the granuloma environment; inhibiting one identified process reduced granuloma formation in a mouse model. This type of work is being used to prioritize targets such as JAK, mTOR, cytokines, and macrophage pathways. Single-cell and spatial transcriptomics study

Biomarker development is another major priority because clinicians currently lack a single test that reliably diagnoses active sarcoidosis, predicts progression, or indicates whether treatment can safely stop. Investigators are combining blood immune signatures, soluble inflammatory markers, tissue analysis, lung function, and FDG-PET imaging, which detects metabolically active inflammation. NIH-supported researchers reported a peptide-based blood immunoassay that distinguished sarcoidosis from other respiratory diseases, but it requires further validation before routine use. Biomarkers in Sarcoidosis NIH blood-test announcement

Leading Institutions and Funding

Major academic contributors include Yale University, which leads JAK-inhibitor research in cutaneous sarcoidosis; the University of Cincinnati, Ohio State University, Cleveland Clinic, and Northwestern University, whose investigators contributed to efzofitimod clinical research; and Dutch pulmonary centers that conducted the PREDMETH trial with support from the Dutch Lung Foundation. JAK1 Inhibition in Sarcoidosis Efzofitimod Phase 1b/2a study First-Line Treatment with Prednisone or Methotrexate Industry participants include aTyr Pharma, Xentria, and Novartis, reflecting increased interest in pathway-directed medicines despite the small size and clinical heterogeneity of the patient population. EFZO-FIT registry record XTMAB-16 trial CMK389 trial

Public and nonprofit funding remains essential. The U.S. National Heart, Lung, and Blood Institute supports sarcoidosis within its granulomatous and rare interstitial lung disease research portfolio, and NIH-supported studies have funded diagnostic and precision-medicine work. In 2024, the Foundation for Sarcoidosis Research announced $200,000 for cardiac sarcoidosis research grants, including projects focused on improving cardiac FDG-PET imaging and spatial analysis of cardiac tissue. NHLBI granulomatous and rare ILD program NIH blood-test announcement FSR cardiac research grants

Strengths, Limitations, and Challenges

The field’s main strengths are a clearer picture of granuloma immunology, better disease-specific outcome measures, and the arrival of randomized trials that test steroid-sparing strategies. The PREDMETH trial offers actionable evidence for methotrexate as an initial treatment option, and single-cell studies offer a rational route toward more personalized therapies. First-Line Treatment with Prednisone or Methotrexate Single-cell and spatial transcriptomics study

The major limitations are biological diversity, uncertain cause, small trial populations, and difficulty separating reversible inflammation from established fibrosis. A drug may improve symptoms or enable steroid tapering without eradicating the disease process, and patient-reported improvements after a missed primary endpoint cannot establish definitive efficacy. Long-term immune suppression also carries infection, metabolic, liver, blood-count, and other safety risks, while access to multidisciplinary specialty care and advanced imaging remains uneven. No available biomarker is sufficiently specific and validated to direct treatment reliably across all patients. EFZO-FIT topline results Biomarkers in Sarcoidosis ERS clinical practice guidelines

Outlook and Future Directions

A cure for sarcoidosis is not close in the sense of an approved treatment that permanently eliminates disease for most patients. The nearer-term objective is more realistic but still consequential: identify molecular subtypes, match patients to targeted steroid-sparing therapies, measure active inflammation accurately, and test whether treatment can be withdrawn without relapse. Milestones to watch include publication of results from JAK- and mTOR-pathway trials, full peer-reviewed analysis and regulatory follow-up of efzofitimod, validation of blood and imaging biomarkers, and trials designed around durable drug-free remission rather than short-term steroid reduction alone. Sarcoidosis: A Clinical Trials Perspective New Therapies for Sarcoidosis

References

Don't see your disease? Request a report